Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tominersen dose-finding study in prodromal and early manifest Huntington's disease
2023-503928-10-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Feb 2023
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of tominersen in Huntington disease (HD) (3 arms), sponsored by Roche. Planned start Feb 2023; status: authorised.
02
Drugs
tominersen
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2023-503928-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503928-10-00.